An antidopaminergic drug used orally, rectally, or intravenously to suppress nausea and vomiting, as a prokinetic agent and for promoting lactation.
It is a specific blocker of dopamine receptors.
It increases gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic.
Trade name is Motilium.
Routes are oral, intravenous, and rectal.
Highly boavailable! with protein binding of 91–93%.
Metabolism is by liver and intestinal first-pass.
Half-life of 7 hours
Excreted via the kidney and in breast milk.
Can be used, together with metoclopramide, cyclizine, and 5HT3 receptor antagonists in the treatment of nausea and vomiting.
Effective for gastroesophageal reflux disease (GERD), as well as for hiatal hernia.
Domperidone is not approved for prescription use in the US.
Does not cross the blood–brain barrier, and therefore can be used in patients with Parkinson’s disease.
Effective in the treatment of gastroparesis.
Effective for pediatric gastroesophageal reflux disease.
By acting as an anti-dopaminergic it increases prolactin secretion, and promotes lactation.
An oral dopamine2 inhibitor.
Associated with QT interval prolongation and cardiac arrhythmias.
The intravenous form of domperidone may be associated with cardiac arrest and arrhythmias.
Acts as a gastrointestinal emptying adjunct and peristaltic stimulant related to its peripheral dopamine receptor-blocking properties.
Facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure.
The antiemetic properties are related to its dopamine receptor-blocking activity at both the chemoreceptor trigger zone and at the gastric level.
It has strong affinities for dopamine receptors found in the chemoreceptor trigger zone, which regulates nausea and vomiting.